NEU Vs Reata, page-49

I have wondered this for a while and wanted to float with the forum for your views.

Is there a chance that we are too valuable or maybe better put, we know how valuable we are if everything goes well and we have 2591 approved in many, many conditions - and we don't want to give it away for less than we know it is?

I don't possess Hottod's research abilities, but I have done some and I cannot find a drug, anywhere in the world, that has the same prospects/potential as 2591. It's got the ability to treat multiple declared Orphan Neurodevelopmental conditions, plus a range of many others. It seemingly has potential to treat non-orphan neurodevelopmental and neurodegenerative conditions and also possibly be taken prophylactically, kind of like a vitamin, but for the brain.

Is there a chance because we know the potential of the drug and subsequent value, we are pricing ourselves out the market? There has been no word from management about serious interest/offers from interested parties. There have been references to general interest, but nothing formal and I have to think that the lack of concrete interest is a result of Management setting expectations that the market does not want to meet. Because we know the value better than others, when we articulate that value there is a baulk from interested parties.

Obviously hypothetical but is something that has been on my mind for a while.

The alternative, wherein nobody is interested in 2591, just does not hold water in my view. There is definite cognitive bias on my part, but if I am trying to be as objective as I can, there is no possible way that there is no interest in 2591.

Hope that makes sense.